Extensively drug-resistant Acinetobacter baumannii: Risk factors for acquisition and prevalent OXA-type carbapenemases-a multicentre study

International Journal of Antimicrobial Agents

Volumn 36, Issue 5, 2010, Pages 430-435

  Park, Yoon Soo ^a   Lee, Hyukmin ^b   Lee, Kkot Sil ^b   Hwang, Seung Sik ^c   Cho, Yong Kyun ^a   Kim, Hyo Youl ^d   Uh, Young ^d   Chin, Bum Sik ^e   Han, Sang Hoon ^e   Jeong, Seok Hoon ^e   Lee, Kyungwon ^e   Kim, June Myung ^e  

^a Gachon University College of Medicine   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

^c Inha University School of Medicine   (South Korea)

^d Wonju Severance Christian Hospital   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

Author keywords

Acinetobacter baumannii; Extensive drug resistance; OXA carbapenemase; Risk factor

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; OXA TYPE CARBAPENEMASE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ADULT; AGE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTERIAL GENE; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INSERTION SEQUENCE; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SOUTH KOREA; TERTIARY HEALTH CARE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CASE-CONTROL STUDIES; CROSS INFECTION; DNA FINGERPRINTING; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; GENOTYPE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 77957686435     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.06.049     Document Type: Article

References (35)

1. Fournier P.E., Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006, 42:692-699.
2. Maragakis L.L., Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008, 46:1254-1263.
3. Lockhart S.R., Abramson M.A., Beekmann S.E., Gallagher G., Riedel S., Diekema D.J., et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007, 45:3352-3359.
4. OXA-carrying imipenem-resistant Acinetobacter spp. in 3 hospitals in Taiwan. Diagn Microbiol Infect Dis 2010, 66:195-199.
5. OXA-23 collected from hospitals in Rio de Janeiro, Brazil. Int J Antimicrob Agents 2009, 34:25-28.
6. Gur D., Korten V., Unal S., Deshpande L.M., Castanheira M. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites. J Med Microbiol 2008, 57:1529-1532.
7. Gales A.C., Jones R.N., Sader H.S. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006, 12:315-321.
8. Giske C.G., Monnet D.L., Cars O., Carmeli Y. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob Agents Chemother 2008, 52:813-821.
9. Falagas M.E., Koletsi P.K., Bliziotis I.A. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006, 55:1619-1629.
10. Falagas M.E., Karageorgopoulos D.E. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008, 46:1121-1122. author reply 1122.
11. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. Document M100-S17. Wayne, PA: CLSI; 2007.
13. Lee K., Chong Y., Shin H.B., Kim Y.A., Yong D., Yum J.H. Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect 2001, 7:88-91.
14. Lee K., Lim Y.S., Yong D., Yum J.H., Chong Y. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 2003, 41:4623-4629.
15. SIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother 2005, 49:4485-4491.
16. Woodford N., Ellington M.J., Coelho J.M., Turton J.F., Ward M.E., Brown S., et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2006, 27:351-353.
17. VIM-2 cassette-containing novel integrons in metallo-β-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob Agents Chemother 2002, 46:1053-1058.
18. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008, 21:538-582.
19. Navon-Venezia S., Ben-Ami R., Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005, 18:306-313.
20. Weingarten C.M., Rybak M.J., Jahns B.E., Stevenson J.G., Brown W.J., Levine D.P. Evaluation of Acinetobacter baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital. Pharmacotherapy 1999, 19:1080-1085.
21. Rodriguez-Bano J., Cisneros J.M., Fernandez-Cuenca F., Ribera A., Vila J., Pascual A., et al. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol 2004, 25:819-824.
22. Manikal V.M., Landman D., Saurina G., Oydna E., Lal H., Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000, 31:101-106.
23. Kohlenberg A., Brummer S., Higgins P.G., Sohr D., Piening B.C., de Grahl C., et al. Outbreak of carbapenem-resistant Acinetobacter baumannii carrying the carbapenemase OXA-23 in a German university medical centre. J Med Microbiol 2009, 58:1499-1507.
24. Harris A.D., Karchmer T.B., Carmeli Y., Samore M.H. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001, 32:1055-1061.
25. Falagas M.E., Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006, 64:7-15.
26. Marchaim D., Navon-Venezia S., Leavitt A., Chmelnitsky I., Schwaber M.J., Carmeli Y. Molecular and epidemiologic study of polyclonal outbreaks of multidrug-resistant Acinetobacter baumannii infection in an Israeli hospital. Infect Control Hosp Epidemiol 2007, 28:945-950.
27. Oteo J., Garcia-Estebanez C., Miguelanez S., Campos J., Marti S., Vila J., et al. Genotypic diversity of imipenem resistant isolates of Acinetobacter baumannii in Spain. J Infect 2007, 55:260-266.
28. Landman D., Quale J.M., Mayorga D., Adedeji A., Vangala K., Ravishankar J., et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med 2002, 162:1515-1520.
29. Donald H.M., Scaife W., Amyes S.G., Young H.K. Sequence analysis of ARI-1, a novel OXA β-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother 2000, 44:196-199.
30. Heritier C., Poirel L., Lambert T., Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005, 49:3198-3202.
31. VIM-2 gene cassettes. J Antimicrob Chemother 2002, 49:837-840.
32. Lee K., Ha G.Y., Shin B.M., Kim J.J., Kang J.O., Jang S.J., et al. Metallo-β-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp. Diagn Microbiol Infect Dis 2004, 50:51-58.
33. Lim Y.M., Shin K.S., Kim J. Distinct antimicrobial resistance patterns and antimicrobial resistance-harboring genes according to genomic species of Acinetobacter isolates. J Clin Microbiol 2007, 45:902-905.
34. Lee J.H., Choi C.H., Kang H.Y., Lee J.Y., Kim J., Lee Y.C., et al. Differences in phenotypic and genotypic traits against antimicrobial agents between Acinetobacter baumannii and Acinetobacter genomic species 13TU. J Antimicrob Chemother 2007, 59:633-639.
35. Lee K., Kim M.N., Choi T.Y., Cho S.E., Lee S., Whang D.H., et al. Wide dissemination of OXA-type carbapenemases in clinical Acinetobacter spp. isolates from South Korea. Int J Antimicrob Agents 2009, 33:520-524.